Extended Release Tablet Of Antidiabetic Drug
Development, optimization and evaluation
Versandkostenfrei!
Versandfertig in 6-10 Tagen
41,99 €
inkl. MwSt.
PAYBACK Punkte
21 °P sammeln!
According to WHO 2012 report 347 million people worldwide have Diabetes. Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. Glipizide has a relatively short elimination half-life (2-4 h) and practically water-insoluble BCS class-II drug thereby requiring two to three times daily dosing in large number of patients, which often leads to non-compliance. The present work was aimed towards the development of extended release formulations of glipizide in order to achieve plasma concentration profile up to ...
According to WHO 2012 report 347 million people worldwide have Diabetes. Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. Glipizide has a relatively short elimination half-life (2-4 h) and practically water-insoluble BCS class-II drug thereby requiring two to three times daily dosing in large number of patients, which often leads to non-compliance. The present work was aimed towards the development of extended release formulations of glipizide in order to achieve plasma concentration profile up to 24 hrs using based on matrix technology resulting in a better patient compliance. Limited work has been performed and published on hydroxy ethyl cellulose and hydroxyl propyl cellulose as an oral extended release hydrophilic matrix system. This book is helpful to the researcher who works with development of extended release matrix tablet formulations using hydroxy ethyl cellulose and hydroxypropyl cellulose.
Andere Kunden interessierten sich für
